IL15/IL15Rα heterodimeric Fc-fusions with extended half-lives

Matthew J. Bennett, Rajat Varma, Christine Bonzon, Rumana Rashid, Kendra N. Avery, Irene W. L. Leung, Liz Bogaert, Suzanne Schubbert, Gregory L. Moore, Seung Y. Chu, Umesh S. Muchhal, John R. Desjarlais

Introduction

- IL15 is a highly active cytokine that stimulates the proliferation and differentiation of T and NK cells, yet has an in vivo half-life of <1 hr which limits its utility as a therapeutic.
- IL15 is produced by monocytes and dendritic cells and functions as a stabilized heterodimeric receptor with membrane-bound IL15Rα present on the same cells.
- On APCs, the IL15/IL15Rα complex is presented in trans to NK cells and CD8+ T cells expressing IL2R and the common gamma chain. It has been shown that recombinant IL15/IL15Rα heterodimer is highly active.
- To create a more druggable IL15 therapeutic, we engineered IL15/IL15Rα heterodimeric Fc-fusions that can be produced by standard industry methods, have high activity, and extended serum half-life.

IL15 is presented in trans to NK and T cells as an IL15/IL15Rα complex on APCs.

Structure of the IL-15-receptor complex: IL15Rα (hetero), IL15, IL15Rα (homo), Common γ chain, IL2Rβ (hetero), γc (hetero)

A

IL15/IL15Rα-Fc heterodimers are engineered for optimal activity and extended serum half-life

Schematic and 3D structural model of IL15/IL15Rα-Fc heterodimer

Analytical SEC of purified IL15/IL15Rα-Fc heterodimer

- Monovalent IL15/IL15Rα(sushi domain) is attached to Xencor’s well-validated heterodimeric Fc domain
- Fc domain is modified to eliminate Fcγ R interactions
- Fc domain may also be modified with Xlendit Fc technology to promote longer half-life
- Produced in high yields and purified by standard methods

B

IL15/IL15Rα-Fc heterodimers promote signaling and cell proliferation in vitro

- STAT5 phosphorylation assay:
  - huPBMCs are treated with IL15/IL15Rα-Fc for 15 minutes, followed by analysis by flow cytometry
  - IL15/IL15Rα-Fc induces potent signaling of CD8+ T cells
- Cell proliferation assay:
  - huPBMCs are treated with IL15/IL15Rα-Fc for 3 days, followed by analysis by flow cytometry
  - IL15/IL15Rα-Fc induces potent in vitro proliferation of NK cells, CD8+ T cells, and to a lesser extent CD4+ T cells

C

In vitro cell proliferation of human PBMCs by IL15/IL15Rα-Fc

- Human lymphocyte, NK cell, CD8+ T cell, and CD4+ T cell counts are significantly increased by IL15/IL15Rα-Fc heterodimers in a dose dependent manner:
- Human IFNγ production is significantly increased by IL15/IL15Rα-Fc heterodimers:

D

IL15/IL15Rα-Fc heterodimers are active in cynomolgus monkeys

- Cynomolgus monkeys (n=3 per group) were given a single IV dose of IL15/IL15Rα-Fc, and lymphocyte proliferation and counts were assessed over time for 21 days
- IL15/IL15Rα-Fc causes significant increases in lymphocyte subsets, peaking at Day 6: increased CD8+/CD4+ T cell ratio is also observed

E

IL15/IL15Rα-Fc heterodimers have antibody-like PK in mice

- IL15/IL15Rα-Fc heterodimers have a much longer half life vs. <1 hr for recombinant IL15
- Longer half-life should allow for greater exposure and a more favorable dosing regimen

Summary

- Engineered IL15/IL15Rα-Fc heterodimers with extended serum half-life have been produced using Xencor’s heterodimeric Fc domain.
- IL15/IL15Rα-Fc heterodimers stimulate potent in vitro and in vivo proliferation and activation of human lymphocytes.
- IL15/IL15Rα-Fc heterodimers are active in cynomolgus monkeys and show expansion of multiple lymphocyte subsets.
- IL15/IL15Rα-Fc heterodimers have extended half-life in mice.
- These results support clinical testing of an IL15/IL15Rα-Fc heterodimer as a novel cytokine therapy in cancer patients.

Contact: jd@xencor.com

© 2017 Xencor, Inc., Monrovia, CA 91016 USA